Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 12Rituximab 10Peripheral Blood Stem Cell Transplantation 8fludarabine phosphate 7Etoposide 5fludarabine 4Radiotherapy 4Filgrastim 4Cytarabine 4venetoclax 3ofatumumab 3Whole-Body Irradiation 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Doxorubicin 3Cyclosporine 3Carmustine 3Bendamustine Hydrochloride 3sargramostim 2romidepsin 2idelalisib 2ibrutinib 2ibritumomab tiuxetan 2Saline Solution 2Prednisone 2Pentetic Acid 2Ondansetron 2O(6)-benzylguanine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Non-Hodgkin × bempegaldesleukin × Clear all
NCT03772288 2023-02-08

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Calithera Biosciences, Inc

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡